In all treatment arms combined, CD45 as a categorical variable (high vs. low) in multivariable analysis was significantly associated with improved RFS (HR 0.75, 95% CI 0.59–0.95, p = 0.02) after adjusting for tumor size, lymph node status, tumor grade, age, and ER/PR status. This evidence concerns the gene PTPRC and neoplasm.